Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

AstraZeneca Buys China Generic Drug Firm; Announces US Layoffs

publication date: Dec 8, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca announced it will increase its China presence by acquiring Guangdong BeiKang Pharmaceutical, a drug maker with five generic injectible anti-infective products. The purchase price for BeiKang, a privately held company, was not disclosed. At the same time, AstraZeneca is laying off 1,150 members of its US-based sales force. More details....

Stock Symbol: (NYSE: AZN)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...